• Services
    • Transformation Consultants
    • Safety Consultants
    • Leadership and Organizational Performance
    • Major Capital Projects
    • High Integrity Turnarounds™
    • The School of Coaching
  • Impact
    • What Clients Say
    • Client Results
  • Insights
    • Articles, Blogs & Poetry
    • Press Releases
    • Events
    • Transformation Talks Podcast
  • People
    • Global Leadership Team and Partners
    • Partners
    • Managing Consultants
    • Board of Directors
    • Founders
  • About Us
    • Our History
    • Our Vision
    • Our Perspective
  • Careers
  • Contact Us
  • Let's Talk

Top 10 Asia Biopharma Clusters 2019

Published by Chloe Handley at October 30, 2019
JMJ Associates Logo
Latest News
  • From the Web

Top 10 Asia Biopharma Clusters 2019

Latest Blogs

Oct 30, 2019


The biopharma industry is growing steadily in Asia Economic indicators such as the increase in public R & D spending across the Asian continent and the increase in both the number of new biopharma companies and the percentage of those companies applying for initial public offerings. Additionally, the number of biotechnology and pharmaceutical patents filed across Asia has exceeded 77 million. Jobs in the biopharmaceutical and biotech industries have continued to rise over the past decade. Here are some of the Top 5 geographic clusters across Asia leading the way in biopharma innovations.

Thailand

Tourists know Thailand is the "Land of Smiles" but soon its moniker can be changed to "Land of Robotics". Thailand has been the worldwide leader in the "bio-economy" when it comes to medical robotics businesses. Thailand's economy is built to incentivize the biopharma industry with a corporate income tax exemption for the development of biotech robotics. There is also a five-year tax exemption for the building and design of automata or mechanization devices and components corporations.

Indonesia

Indonesia hasn't led in biotech IPOs in the past several years but aims to change. Indonesian President Joko Widodo has proposed cutting the corporate tax rate for newly listed biopharma companies to 17% for the first five years after their initial public offering. That tax rate matches that of Singapore and is a lower rate than Malaysia, Thailand, and Vietnam.

Malaysia

The Malaysian government is coming to the tail end of a 15-year National Biotechnology Policy that is just about to expire in 2020. The goal of this policy is to expand the biopharma industry to just over 5% of its Gross Domestic Product. They have gone so far as to develop a Malaysian Bioeconomy Development Corporation to see the effort through as it pertains to science, agriculture, and the various biotech economies.

Singapore

Singapore has the highest quantity of corporate pharmaceutical manufacturers and biotech developers in the Asian Pacific (APAC) region. For example, PerkinElmer just opened in Singapore in May and is the biggest lab instrument plant on earth. Singapore continues to encourage biopharma developers such as Aslan Bio to thrive in the region.

Taiwan

President Tsai Ing-wen launched the Innovative Industries Plan, in 2016 to develop Taiwanese biotech and biopharma homegrown industries. Taiwan is set to increase the growth of biopharma, biotech and medical device industries by a combined $32 billion by the year 2025. Taiwan milestone includes developing the production of new medical treatments with precision medicine in mind. Taiwan also hoped to train 120 new biopharma industry professionals in the coming year.

Australia

Australia has made the list by encouraging new biopharma industries to develop in the research stage. The "Down Under" country has new laws that took effect in October 2019 that will enable researchers to use CRISPR and other innovative gene-editing biotechnology on the condition that new genetic material is created. Up to this point, genetic researchers and biopharma scientists were required to secure biosafety panel approval, a rule the biopharma and biotech industries have previously said have hampered gene therapy efforts.

Read the source article at genengnews.com



A year after transactions involving “research and development in biotechnology” and 26 other “critical technology” industries were made subject to review by the Committee on Foreign Investment in the United States (CFIUS), President Donald Trump’s Administration has signaled a desire to keep an even closer eye on such deals. The new rules could further reduce foreign direct investment in the United States by overseas investors, including Asian firms and wealthy individuals increasingly flush with capital as biopharma has grown in Asia.

The Trump Administration has proposed regulations to implement the Foreign Investment Risk Review Modernization Act (FIRRMA) of 2018 by further expanding CFIUS’ jurisdiction beyond transactions that could result in control of a U.S. business shifting to overseas investors, to also include a noncontrolling direct or indirect investment by a foreign person as spelled out by the U.S. Treasury Department.

The CFIUS expansion appears to explain a drop in Chinese foreign direct investment (FDI) into U.S. biopharmas. According to PitchBook, Chinese investors participated in $725 million worth of venture capital financings for U.S. biopharmas during the first half of 2019—down 56% from $1.65 billion during January–June 2018.

Read the source article at genengnews.com


View All Client Results

Capital Projects Client Results
DSME Completes TCO FGP WPMP Fabrication Safely and ahead of Schedule for the Tengizchevroil Expansion Project
DSME Completes
Client Results Manufacturing
Global Manufacturing Corporation Reduces Quality Defects and Improves Bottom-Line Performance
One of the worl
DSHI Fabrication Yards in Korea Builds Strong Safety Culture on TCO FGP Major Capital Project
Client Results Safety
DSHI Fabrication Yards in Korea Builds Strong Safety Culture on TCO FGP Major Capital Project
At Korean fabri
Japanese Engineering & Construction Corporat Achieves Breakthrough Improvement in Safety Performance
Client Results Safety
Japanese Engineering & Construction Corporation Achieves Breakthrough Improvement in Safety Performance
The JGC Corpora
Russian Petroleum Operations Company Achieves a Shift in its Health and Safety Culture
Client Results Safety
Russian Petroleum Operations Company Achieves a Shift in its Health and Safety Culture in 9 Months
SPD had been wo



From the Web

Your Coronavirus Questions, Answered by Experts
Coronavirus From the web
Your Coronavirus Questions, Answered by Experts.
With the coronavirus sending us all indo
coronavirus
From the web
Working from home because of coronavirus? Be careful what you download to keep cybersafe
Welcome to the new normal: working from
Increase engagement through communication
From the web
Increase engagement through communication
Safety training sessions and conducting
The biopharma industry is growing steadily in Asia Economic indicators such as the increase in public R & D spending across the Asian continent and the increase in both the number of new biopharma companies and the percentage of those companies applying for initial public offerings.

  • Author
Chloe Handley
Chloe Handley Administrator
Chloe Handley has progressed to Global Senior Marketing and Communications Specialist since joining JMJ in 2011. Chloé’s experience spans both agency and in-house; working with brands such as Sodexo, Rics, Neopost, Harley Medical Group, Lancashire Constabulary, Wyeth Pharmaceuticals and Coca-Cola. Her experience spans lead generation through digital design and marketing, brand narrative and consistent business and client-focused targeted marketing communications. Chloé’s responsible for managing brand development and marketing and communication strategies across JMJ, helping to drive growth and maintain JMJ’s market lead position. She works with internal teams to develop tailored marketing plans across a range of communications channels – in line with JMJ’s business development objectives.
follow me
JMJ
  • Corporate Headquarters
    Arboretum Plaza One
    9442 N. Capital of Texas Highway, Suite 450,
    Austin, Texas 78759
  • +1 (512) 795-0795
  • Email Us

Services

  • Transformation Consultants
  • Safety Consultants
  • Leadership and Organizational Performance
  • Major Capital Projects
  • High Integrity Turnarounds™
  • The School of Coaching

Locations

  • Americas Office – Austin
  • APAC Office – Singapore
  • EMEA Office – London
  • Middle East Office – Doha
  • Kazakhstan Office – Atyrau
  • South Korea Office – Seoul
  • Australia Office – Perth

Connect

  • linkedin
  • facebook
  • twitter
  • Youtube
Privacy | Terms of Use | Trademarks | Accessibility | Cookie Policy | Feedback | Site Map |

© 2020 JMJ Associates LLP. All rights reserved. Republication or redistribution of JMJ Associates content or logo, including by framing or similar means, is prohibited without the prior written consent of JMJ Associates.

    Start Unlocking Human Performance


    Arrange a call with one of our consultants today. Please complete your details below:

    • This field is for validation purposes and should be left unchanged.